HABP/VABP and Gram-Negative Resistance: Pathways to Early Effective Therapy

Comprehensive slideset featuring data on key concepts in HABP/VABP and gram-negative resistance management, including epidemiology, risk factors, burden of disease, diagnostics, and optimizing treatment regimens to minimize the time to effective therapy.
Lilian Abbo Headshot
Lilian Abbo, MD, FIDSA
Keith S. Kaye, MD, MPH
Jason Pogue Headshot
Jason M. Pogue, PharmD
Format: Microsoft PowerPoint (.ppt)
File Size: 526 KB
Released: February 18, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Related Content

Expert faculty discuss ways to improve the empiric treatment of HABP/VABP in the ICU in this commentary from Clinical Care Options (CCO)

person default Marion Elligsen, BScPhm, MSc, RPh, ACPR Keith S. Kaye, MD, MPH Andrew Shorr, MD, MPH, MBA Released: November 18, 2022

Learn from experts about strategies to improve timely, effective antibiotic therapy in patients with HABP/VABP at risk for multidrug resistance, from Clinical Care Options (CCO)

Clinical Care Options (CCO) presents expert faculty discussing RSV in certain adult populations and the development of RSV vaccines

John J. Russell, MD, FAAFP
Program Director
Laura Hurley, MD, MPH Pamela Rockwell, DO, FAAFP
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Registered Nurses: 1.5 Nursing contact hours Released: October 28, 2022 Expired: October 27, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings